Business Insider

Sanofi's Toujeo® met main objective in head-to-head study versus insulin degludec

PARIS, Dec. 4, 2017 /PRNewswire-USNewswire/ -- Sanofi's Toujeo® met the primary study objective in the first large head-to-head clinical trial 1, called BRIGHT study, comparing Toujeo with insulin ...
Medscape

EU Gives Green Light to Toujeo, a Better Insulin Glargine?

The European Union has given the nod to a new formulation of insulin glargine (Toujeo, Sanofi), which is a higher-strength insulin (300 units/mL) than the existing insulin glargine product on the ...
The American Journal of Managed Care

FDA Approves Toujeo, Basal Insulin Seen as Successor to Lantus

The FDA on February 25, 2015, approved the basal insulin Toujeo, which Sanofi sees as a successor to Lantus to treat patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM). Toujeo, insulin ...
News Medical

Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Toujeo ® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve ...
PharmiWeb

Toujeo® (insulin glargine) EU licence extended for use in adolescents and children from the age of 6 years with diabetes mellitus

READING, ENGLAND – 10 January 2020 – Sanofi has announced that the European Commission (EC) has expanded the current indication for Toujeo ® (insulin glargine 300 units/mL) to include children and ...
The American Journal of Managed Care

Sanofi Says Toujeo Met Objective in Head-to-Head Insulin Study

Sanofi’s newest insulin met its primary objective in a large head-to-head trial that compared it with its chief competitor. Sanofi’s newest insulin, Toujeo, met its primary objective in a large ...
Medindia

Sanofi Announces Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) in Japanese People with Uncontrolled Diabetes

- In EDITION JP I and II, investigational Toujeo ® demonstrated similar blood sugar control with fewer night-time low blood sugar events over 6-month study period, vs. Lantus ® - Sanofi (EURONEXT : ...
FiercePharma

EASD: Sanofi's Toujeo bests Lantus at holding off hypoglycemia, studies show

LISBON, Portugal—Sanofi’s longer-acting basal insulin Toujeo, a follow-up to its own long-dominant product Lantus, beat the older medication at holding off hypoglycemia, both by day and by night. In ...
Nasdaq

Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes

BRIDGEWATER, N.J., Nov. 4, 2019 /PRNewswire/ -- Children and adolescents (aged 6 to 17 years) living with type 1 diabetes achieved comparable reduction in average blood sugar (HbA1c) and similar risk ...
Monthly Prescribing Reference

Switching to Toujeo Reduced Hypoglycemia Risk in Older Patients

Study patients who switched to Toujeo were 57% less likely to have hypoglycemia at the 6-month follow-up (OR 0.432, 95% CI: 0.307-0.607; P Findings from a real-world observational study showed a ...
Medindia

Switching to Toujeo® in a real-world setting produced a similar number of severe low blood sugar events as insulin degludec

LOS ANGELES, Nov. 30, 2017 /PRNewswire/ -- Adults with type 2 diabetes who switched their basal insulin therapy to Toujeo ® or insulin degludec, experienced similar numbers of low blood sugar ...